Loading...
  • analogues
  • Ribonucleoside analogues have potential utility as anti-viral, -parasitic, -bacterial and -cancer agents. (ku.edu)
  • Here we test the hypothesis that triphosphorylated metabolites of therapeutic ribonucleoside analogues are substrates for cellular RNA polymerases. (ku.edu)
  • We have used ribonucleoside analogues with activity against HCV as model compounds for therapeutic ribonucleosides. (ku.edu)
  • We have included ribonucleoside analogues containing 2′-C-methyl, 4′-methyl and 4′-azido substituents that are non-obligate chain terminators of the HCV RNA polymerase. (ku.edu)
  • We show that all of the anti-HCV ribonucleoside analogues are substrates for human mitochondrial RNA polymerase (POLRMT) and eukaryotic core RNA polymerase II (Pol II) in vitro. (ku.edu)
  • A series of N6-aminopurine-9-b-D-ribonucleosides and ribose-modified 30-C-methyl analogues substituted at N6-position with a small group like hydroxy, methoxy or amino group or at C2(N6) position have been synthesized and tested against a panel of human leukemia and carcinoma cell lines. (unicam.it)
  • reaction
  • Synthesis and enzymatic evaluation of the guanosine analogue 2-amino-6-mercapto-7-methylpurine ribonucleoside (MESG): insights into the phosphorolysis reaction mechanism based on the blueprint transition state: SN1 or S N2? (scielo.br)
  • Full
  • A modified experimental procedure for the synthesis of MESG (2-amino-6-mercapto-7-methylpurine ribonucleoside) 1 has been successfully performed and its full characterization is presented. (scielo.br)
  • treatment
  • Development of antiviral ribonucleosides for treatment of hepatitis C virus (HCV) infection has been hampered by appearance of toxicity during clinical trials that evaded detection during preclinical studies. (ku.edu)